Patents Assigned to Ma'at
  • Channelled nonwoven with reduced surface expansion of liquid for the production of sanitary towels and relative process of manufacture
    Patent number: 9169586
    Abstract: A sanitary towel for physiological liquids includes as topsheet layer a layer of nonwoven cotton (10) having density which varies transversely and provided with a first plurality of longitudinal lines (1) along which the textile has a higher density of fibers with respect to the rest of the textile, each of the longitudinal lines (1) of the first plurality of lines being alternated with a respective longitudinal line (2) of a second plurality of longitudinal lines (2) along which the textile has a lower density of fibers with respect to the longitudinal lines (1).
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: October 27, 2015
    Assignee: FA-MA JERSEY S.P.A.
    Inventor: Marco Maranghi
  • ANTIBODIES TO VLA-1
    Publication number: 20150299323
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: January 15, 2015
    Publication date: October 22, 2015
    Applicant: BIOGEN MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • ARC SUPPRESSOR FOR FUSIBLE ELEMENTS
    Publication number: 20150294828
    Abstract: An arc suppressor fixable to a fusible element to suppress electrical arcs and prevent the spread of electric arc “burn-back.” The arc suppressor includes first and second inner members comprised of pre-cured silicone rubber, and first and second outer members comprised of an arc suppressing material (e.g., melamine). The inner and outer members form a sandwich around a portion of the fusible element, wherein the first inner member is located adjacent to a first surface of the fusible element and the second inner member is located adjacent to an opposing second surface of the fusible element. The first outer member is located adjacent to the first inner member and the second outer member is located adjacent to the second inner member. Mechanical fasteners tightly engage together the first and second inner members, the fusible element, and the first and second outer members.
    Type: Application
    Filed: April 14, 2014
    Publication date: October 15, 2015
    Applicant: Mersen USA Newburyport-MA, LLC
    Inventor: Robert M. Burge
  • Methods of Using FVIII Polypeptide
    Publication number: 20150266944
    Abstract: The present invention provides methods of reducing or decreasing the annualized bleeding rate of a human subject having hemophilia by administering a long acting Factor VIII polypeptide. The long-acting FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia. The present invention relates generally to the field of therapeutics for hemostatic disorders.
    Type: Application
    Filed: October 30, 2013
    Publication date: September 24, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Haiyan Jiang, Srividya Neelakantan, Ivan Nestorov, Shuanglian Li
  • FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF
    Publication number: 20150266943
    Abstract: The present invention includes a chimeric protein comprising a VWF protein with D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain of a VWF fragment is associated with a FVIII polypeptide chain linked to an XTEN sequence. The VWF fragment polypeptide chain can prevent or inhibit binding of endogenous VWF to FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to FVIII protein, VWF fragment can extend half-life of chimeric protein comprising FVIII protein. The invention includes nucleotides, vectors, host cells, use of VWF fragment, or chimeric proteins.
    Type: Application
    Filed: July 10, 2013
    Publication date: September 24, 2015
    Applicants: AMUNIX OPERATING INC., BIOGEN MA INC.
    Inventors: Ekta Seth Chhabra, Tongyao Liu, Pei-yun Chang, Robert T. Peters, John Kulman
  • Compositions and methods for increasing vascularization
    Patent number: 9138461
    Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: September 22, 2015
    Assignees: Biogen MA Inc., INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat
  • Methods of Using FIX Polypeptides
    Publication number: 20150252345
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Application
    Filed: September 25, 2013
    Publication date: September 10, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
  • Purification of immunoglobulins
    Patent number: 9127043
    Abstract: The present invention pertains to improved methods of using dye-ligand affinity chromatography for the isolation of antibodies or proteins comprising an antibody fragment (such as Fc fusion proteins) from a mixture of undesirable contaminants. In particular, the use of an organic polymer such as polyethylene glycol (PEG) in the elution phase of an antibody/dye-ligand chromatography isolation procedure results in improved separation of target antibodies from undesirable contaminants. The methods described herein are particularly useful in separating or removing antibody aggregates, misfolded antibodies, and virus contaminants from target antibodies.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: September 8, 2015
    Assignee: BIOGEN MA INC.
    Inventors: Robert S. Gronke, Héctor Zaanoni
  • Polyalkylene Polymer Compounds and Uses Thereof
    Publication number: 20150246097
    Abstract: The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.
    Type: Application
    Filed: August 30, 2013
    Publication date: September 3, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: KoChung Lin, Blake Pepinsky, Ling Ling Chen, Donna M. Hess, Edward Y. Lin, Russell C. Petter, Darren P. Baker
  • ATX MODULATING AGENTS
    Publication number: 20150246063
    Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
    Type: Application
    Filed: July 26, 2013
    Publication date: September 3, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Zhaohui Shao, Lihong Sun, Arthur Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Method of isolating biomacromolecules using low pH and divalent cations
    Patent number: 9109015
    Abstract: The present invention is related to a method of isolating a biological macromolecule in a composition. Specifically, the present invention is directed to a method of isolating a biomacromolecule in a composition containing an impurity, the method comprising (a) lowering the pH of the composition, (b) adding a divalent cation to the composition, and (c) separating the biomacromolecule from the impurity.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: August 18, 2015
    Assignee: BIOGEN MA INC
    Inventors: Jonathan Romero, James Chrostowski, Philippe Georges De Vilmorin, Jennifer Yun Case
  • Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation
    Patent number: 9107884
    Abstract: The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a Sema6A polypeptide.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: August 18, 2015
    Assignees: BIOGEN MA INC., CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE
    Inventors: Alain Chedotal, Sha Mi, Frederic Bernard
  • Regeneration of chromatography material
    Patent number: 9102709
    Abstract: Methods and kits for regenerating antibody binding resins are provided. In some embodiments the methods include a first step of washing an antibody binding resin with a reducing solution, followed by a second step of washing the antibody binding resin with a chaotropic solution.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 11, 2015
    Assignee: Biogen MA Inc.
    Inventors: Asif Ladiwala, John Pieracci
  • DISEASE PROGRESSION PARAMETERS AND USES THEREOF FOR EVALUATING MULTIPLE SCLEROSIS
    Publication number: 20150220693
    Abstract: Methods, systems and kits to detect and/or quantify disease progression in a subject having a progressive form of MS are disclosed.
    Type: Application
    Filed: August 8, 2013
    Publication date: August 6, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Diego Cadavid, Deborah Ann Kinch, Sophia Lee, Lei Xu
  • TACI AS AN ANTI-TUMOR AGENT
    Publication number: 20150218247
    Abstract: A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent.
    Type: Application
    Filed: February 25, 2015
    Publication date: August 6, 2015
    Applicants: BIOGEN IDEC MA INC.
    Inventors: Christine Ambrose, Jeffrey Thompson, Paul Rennert, Pascal Schneider
  • METHODS FOR THE DETECTION OF JC POLYOMA VIRUS
    Publication number: 20150219651
    Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: August 6, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Leonid Gorelik, Alexey Lugovskoy
  • Antibodies against monocyte chemotactic proteins
    Patent number: 9096665
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: August 4, 2015
    Assignee: Biogen MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Method of supplementing culture media to prevent undesirable amino acid substitutions
    Patent number: 9096879
    Abstract: The present invention relates to methods of reducing substitution of amino acids during the production of polypeptides of interest in mammalian cells. By varying the concentration of amino acids in the culture medium, heterogeneity of the polypeptide's amino acid sequence is decreased, leading to higher yields of functional protein.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: August 4, 2015
    Assignee: BIOGEN MA INC.
    Inventors: Anurag Khetan, Yao-ming Huang, Jana Dolnikova, Nels Pederson, Helena Yusuf-Makagiansar, Paul Chen, Thomas Ryll
  • Methods of evaluating BAFF
    Patent number: 9097726
    Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: August 4, 2015
    Assignee: Biogen MA Inc.
    Inventors: Yen-Ming Hsu, Susan Kalled
  • Package
    Patent number: D741703
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 27, 2015
    Assignee: Biogen MA Inc.
    Inventors: Christine P. Janson, Ethan B. Jacoby